NCT00365716View on ClinicalTrials.gov

Dose-Ranging Study of Quadrivalent Human Papillomavirus (HPV) (Types 6,11,16,18) L1 Virus-Like Particle (VLP) Vaccine (V501-007)(COMPLETED)

PHASE2CompletedINTERVENTIONAL
Enrollment

1,158

Participants

Timeline

Start Date

May 31, 2000

Primary Completion Date

May 31, 2004

Study Completion Date

September 30, 2009

Conditions
Papillomavirus InfectionsGenital Diseases, Female
Interventions
BIOLOGICAL

Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 20/40/40/20

20/40/40/20 formulation of quadrivalent human papillomavirus (HPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.

BIOLOGICAL

Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 40/40/40/40

40/40/40/40 formulation of quadrivalent human papillomavirus (HPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.

BIOLOGICAL

Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 80/80/40/80

80/80/40/80 formulation of quadrivalent human papillomavirus (qHPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.

BIOLOGICAL

Placebo (mcg) (Aluminum Adjuvant)225

placebo containing 225 mcg of aluminum adjuvant per dose at Day 1, Month 2, and Month 6.

BIOLOGICAL

Placebo (mcg) (Aluminum Adjuvant) 450

placebo containing 450 mcg of aluminum adjuvant per dose at Day 1, Month 2, and Month 6.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00365716 - Dose-Ranging Study of Quadrivalent Human Papillomavirus (HPV) (Types 6,11,16,18) L1 Virus-Like Particle (VLP) Vaccine (V501-007)(COMPLETED) | Biotech Hunter | Biotech Hunter